ArticleCancer immunology, immunotherapy : CII2026

Safety and feasibility of 5T4 antibody-coupled allogeneic NK cell therapy for solid tumors: a first-in-human phase 1 trial.

Liangjie Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.